🚀
Enjoy a 7-Day Free Trial Thru Dec 05, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Drug Manufacturers
Johnson & Johnson (LIM:JNJ)
News
Johnson & Johnson
LIM
:JNJ (USA) Â
Ordinary Shares
$ 160.00
(0%)
Nov 27
P/E:
25.69
P/B:
5.33
Market Cap:
$ 374.14B
Enterprise V:
$ 389.60B
Volume:
10.00
Avg Vol (2M):
23.00
Warning! GuruFocus detected 3 Medium warning signs with JNJ.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
10.00
Market Cap $:
374.14B
PE Ratio:
25.69
Avg Vol (2M):
23.00
Enterprise Value $:
389.60B
PB Ratio:
5.33
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Johnson & Johnson (LIM:JNJ) Stock News, Headlines & Updates
Johnson & Johnson Stock News from GuruFocus
Total 51
1
2
Nov 26, 2024
Navigating Market Uncertainty: Intrinsic Value of Johnson & Johnson
GuruFocus News
•
5:00am
Nov 22, 2024
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
PRNewswire
•
8:00am
Nov 19, 2024
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
PRNewswire
•
9:00am
Nov 18, 2024
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
PRNewswire
•
4:00pm
Johnson & Johnson (JNJ) Faces Restructuring and Layoffs Amidst Local Market Challenges
GuruFocus News
•
8:30am
Nov 14, 2024
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
PRNewswire
•
10:00am
Nov 12, 2024
The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value
GuruFocus News
•
5:00am
Nov 11, 2024
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
PRNewswire
•
4:00pm
Nov 08, 2024
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
PRNewswire
•
7:00am
Nov 07, 2024
FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment
Muslim Farooque
•
1:46pm
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
PRNewswire
•
8:00am
Oct 29, 2024
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus News
•
6:00am
Oct 28, 2024
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
PRNewswire
•
7:00am
Oct 25, 2024
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
PRNewswire
•
8:00am
Oct 24, 2024
Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
PRNewswire
•
8:00am
Decoding Johnson & Johnson (JNJ): A Strategic SWOT Insight
GuruFocus News
•
11:02pm
Oct 16, 2024
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst Litigation Challenges
GuruFocus News
•
1:00am
Q3 2024 Johnson & Johnson Earnings Call Transcript
GuruFocus News
•
11:09pm
Oct 15, 2024
Johnson & Johnson Reports Robust Q3 EPS but Soft FY24 Guidance
GuruFocus News
•
10:14am
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
PRNewswire
•
8:00am
Johnson & Johnson (JNJ) Q3 Earnings Surpass Expectations Driven by Cancer Drug Sales
GuruFocus News
•
7:31am
Johnson & Johnson Q3 2024 Earnings: Revenue Surpasses Estimates at $22.5 Billion, EPS Falls Short at $1.11
GuruFocus News
•
6:51am
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus News
•
6:00am
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
Business Wire
•
6:00am
Johnson & Johnson Reports Q3 2024 Results
Business Wire
•
6:00am
J&J Reports Strong Earnings, Grapples with Ongoing Legal Challenges
Khac Phu Nguyen
•
5:58am
Oct 10, 2024
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
Business Wire
•
4:00pm
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
PRNewswire
•
8:00am
Oct 09, 2024
Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million
GuruFocus News
•
10:31am
Johnson & Johnson Completes Acquisition of V-Wave
Business Wire
•
8:00am
Oct 08, 2024
Johnson & Johnson (JNJ) Halts TAR-200 Bladder Cancer Trial, Future FDA Plans Remain
GuruFocus News
•
1:50am
Oct 04, 2024
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
Business Wire
•
4:00pm
Oct 01, 2024
Unlocking Intrinsic Value: Analysis of Johnson & Johnson
GuruFocus Research
•
6:00am
Sep 30, 2024
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
PRNewswire
•
4:00pm
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
PRNewswire
•
8:00am
Sep 27, 2024
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
PRNewswire
•
4:00pm
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
PRNewswire
•
1:00pm
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
PRNewswire
•
1:00pm
TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
PRNewswire
•
8:00am
Sep 20, 2024
Attorneys Vow to Oppose J&J's Third Bankruptcy Attempt
Business Wire
•
6:00pm
Total 51
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news